Tags

Type your tag names separated by a space and hit enter

Identification of a predictive biomarker for the beneficial effect of a Kampo (Japanese traditional) medicine keishibukuryogan in rheumatoid arthritis patients.
Clin Biochem 2007; 40(15):1113-21CB

Abstract

OBJECTIVES

Kampo (Japanese traditional herbal) medicines are now ethically used in Japan as pharmaceutical grade prescription drugs. However, there are distinct groups of responders and non-responders to Kampo medicines. We searched for biomarker candidates to discriminate responders from non-responders to keishibukuryogan (KBG); one of the most frequently used Kampo medicines.

DESIGN AND METHODS

A combination of SELDI technology and a decision tree analysis with proprietary developed bioinformatics tools was applied to 41 (32 for tree construction and 9 for validation test) plasma samples obtained from rheumatoid arthritis (RA) patients. A candidate biomarker protein was identified using LC-MS/MS.

RESULTS

The constructed tree with measurable reliability contained only a single peak which was identified as haptoglobin alpha 1 chain (Hpalpha1).

CONCLUSION

Hpalpha1 is a biomarker candidate for discriminating responders from non-responders to KBG treatment for RA. The present results may open the way to the establishment of "evidence-based" complementary and alternative medicine.

Authors+Show Affiliations

Central Research Laboratories, Tsumura and Co., Ibaraki, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Validation Studies

Language

eng

PubMed ID

17673196

Citation

Ogawa, Kazuo, et al. "Identification of a Predictive Biomarker for the Beneficial Effect of a Kampo (Japanese Traditional) Medicine Keishibukuryogan in Rheumatoid Arthritis Patients." Clinical Biochemistry, vol. 40, no. 15, 2007, pp. 1113-21.
Ogawa K, Kojima T, Matsumoto C, et al. Identification of a predictive biomarker for the beneficial effect of a Kampo (Japanese traditional) medicine keishibukuryogan in rheumatoid arthritis patients. Clin Biochem. 2007;40(15):1113-21.
Ogawa, K., Kojima, T., Matsumoto, C., Kamegai, S., Oyama, T., Shibagaki, Y., ... Saiki, I. (2007). Identification of a predictive biomarker for the beneficial effect of a Kampo (Japanese traditional) medicine keishibukuryogan in rheumatoid arthritis patients. Clinical Biochemistry, 40(15), pp. 1113-21.
Ogawa K, et al. Identification of a Predictive Biomarker for the Beneficial Effect of a Kampo (Japanese Traditional) Medicine Keishibukuryogan in Rheumatoid Arthritis Patients. Clin Biochem. 2007;40(15):1113-21. PubMed PMID: 17673196.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Identification of a predictive biomarker for the beneficial effect of a Kampo (Japanese traditional) medicine keishibukuryogan in rheumatoid arthritis patients. AU - Ogawa,Kazuo, AU - Kojima,Tetsuko, AU - Matsumoto,Chinami, AU - Kamegai,Satoshi, AU - Oyama,Takuya, AU - Shibagaki,Yukari, AU - Muramoto,Hiroshi, AU - Kawasaki,Tetsuo, AU - Fujinaga,Hiroshi, AU - Takahashi,Kozo, AU - Hikiami,Hiroaki, AU - Goto,Hirozo, AU - Kiga,Chizuru, AU - Koizumi,Keiichi, AU - Sakurai,Hiroaki, AU - Shimada,Yutaka, AU - Yamamoto,Masahiro, AU - Terasawa,Katsutoshi, AU - Takeda,Shuichi, AU - Saiki,Ikuo, Y1 - 2007/07/03/ PY - 2007/02/01/received PY - 2007/05/24/revised PY - 2007/06/09/accepted PY - 2007/8/4/pubmed PY - 2007/12/20/medline PY - 2007/8/4/entrez SP - 1113 EP - 21 JF - Clinical biochemistry JO - Clin. Biochem. VL - 40 IS - 15 N2 - OBJECTIVES: Kampo (Japanese traditional herbal) medicines are now ethically used in Japan as pharmaceutical grade prescription drugs. However, there are distinct groups of responders and non-responders to Kampo medicines. We searched for biomarker candidates to discriminate responders from non-responders to keishibukuryogan (KBG); one of the most frequently used Kampo medicines. DESIGN AND METHODS: A combination of SELDI technology and a decision tree analysis with proprietary developed bioinformatics tools was applied to 41 (32 for tree construction and 9 for validation test) plasma samples obtained from rheumatoid arthritis (RA) patients. A candidate biomarker protein was identified using LC-MS/MS. RESULTS: The constructed tree with measurable reliability contained only a single peak which was identified as haptoglobin alpha 1 chain (Hpalpha1). CONCLUSION: Hpalpha1 is a biomarker candidate for discriminating responders from non-responders to KBG treatment for RA. The present results may open the way to the establishment of "evidence-based" complementary and alternative medicine. SN - 0009-9120 UR - https://www.unboundmedicine.com/medline/citation/17673196/Identification_of_a_predictive_biomarker_for_the_beneficial_effect_of_a_Kampo__Japanese_traditional__medicine_keishibukuryogan_in_rheumatoid_arthritis_patients_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0009-9120(07)00252-4 DB - PRIME DP - Unbound Medicine ER -